Alan Huang - Concepedia

Author

Alan Huang

Novartis (Switzerland)ORCID

Also Known As

A Huang, A. Huang, Alan Huang, Anran Huang, Huang, Alan, Huang, Alan Lo-Chin, Sanders, Melinda, Shuba Gopal, alan huang

351

Publications

8.7K

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Novartis (United States)Massachusetts General Hospital Memorial Sloan Kettering Cancer Center Harvard University

About

Alan Huang is an author at Novartis (Switzerland) specializing in medicine, tumor biology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	24	5.1K
2	Engineering	3	3	697
3	Natural Sciences	3	3	642
4	Biochemistry	2	2	118
5	Health Sciences	1	1	462

Alan Huang

Publications

Citations

H-Index

Page 1

	Year	Citations
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors Garrett M. Frampton, Siraj M. Ali, Mark R. Rosenzweig, Cancer Discovery	2015	782
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor Dejan Juric, Pau Castel, Malachi Griffith, Nature Signal TransductionClinical ResistanceSignaling PathwayMedicineProtein Phosphorylation	2014	561
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas Piro Lito, Christine A. Pratilas, Eric W. Joseph, Cancer Cell Signal TransductionCell RegulationMedicineReceptor Tyrosine KinaseProfound Feedback Inhibition	2012	551
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor Sauveur-Michel Maira, Sabina Pecchi, Alan Huang, Molecular Cancer Therapeutics PharmacotherapyDifferent Selectivity ProfileChemical BiologyPharmaceutical ChemistryTumor Biology	2011	524
Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials Christine Fritsch, Alan Huang, Christian Chatenay‐Rivauday, Molecular Cancer Therapeutics Pten MutationSomatic Pik3ca MutationsPharmacotherapyCancer BiologyTumor Biology	2014	462
Single-vector inducible lentiviral RNAi system for oncology target validation Dmitri Wiederschain, W Nicolson Susan, Lin Chen, Cell Cycle EngineeringOncology Target ValidationCancer BiologyTumor BiologyMolecular Diagnostics	2009	453
CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors Sadhna Vora, Dejan Juric, Nayoon Kim, Cancer Cell Pi3k InhibitorsBreast OncologyMedicineReceptor Tyrosine KinaseBreast Cancer	2014	428
Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in <i>PIK3CA</i>-Altered Solid Tumors: Results From the First-in-Human Study Dejan Juric, Jordi Rodón, Josep Tabernero, Journal of Clinical Oncology Breast OncologySingle-agent AlpelisibSolid TumorsCancer ManagementPathology	2018	425
mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in <i>PIK3CA</i> -Mutant Breast Cancer Moshe Elkabets, Sadhna Vora, Dejan Juric, Science Translational Medicine	2013	344
AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas Moshe Elkabets, Evangelos Pazarentzos, Dejan Juric, Cancer Cell OncologyPi3kα InhibitionSignaling PathwayCell SignalingMedicine	2015	331

Page 1